Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

In the CHAMPION PHOENIX trial, cangrelor reduced the primary composite end point of death, myocardial infarction (MI), ischemia-driven revascularization, or stent thrombosis at 48 hours. This study aimed to explore the impact of event adjudication and the prognostic importance of MI reported by a clinical events committee (CEC) or site investigators (SIs).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Circ Cardiovasc Interv

Title: Circulation. Cardiovascular interventions

Publisher: Ovid Technologies (Wolters Kluwer Health)

ISSN (Electronic): 1941-7632

ISSN (Print): 1941-7640

Publication date (Electronic): July 2019

Volume: 12

Issue: 7

Affiliations

[1 ] Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, CA (C.B.O., K.W.M.).

[2 ] Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany (C.B.O.).

[3 ] Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA (D.L.B.).

[4 ] University of Pavia, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy (S.L.).

[5 ] Columbia University Medical Center and the Cardiovascular Research Foundation, New York City, NY (G.W.S.).

[6 ] Beth Israel Deaconess Medical Center, Division of Cardiology, Boston, MA (C.M.G.).

[7 ] FACT (French Alliance for Cardiovascular Clinical Trials), DHU FIRE, INSERM Unité 1148, Université Paris-Diderot, and Hôpital Bichat, Assistance-Publique-Hôpitaux de Paris, Paris, France, and NHLI, Imperial College, Royal Brompton Hospital, London, United Kingdom (P.G.S.).

[8 ] Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany (C.W.H.).

[9 ] Duke University Medical Center, Durham, NC (M.D.W., S.M., R.D.L.).

[10 ] Scripps Clinic and Scripps Translational Science Institute, La Jolla, CA (M.J.P.).

[11 ] Elysis Llc, Carlisle, MA (J.P.).

[12 ] Green Lane Cardiovascular Service, Auckland, New Zealand (H.D.W.).

[13 ] Department of Medicine, Stanford University School of Medicine, Stanford, CA (R.A.H.).

Article

DOI: 10.1161/CIRCINTERVENTIONS.118.007342

PubMed ID: 31296081

SO-VID: 3c5a4cff-80ac-4d6b-8d45-2de878d7201e

History

Keywords: biomarker,clopidogrel,myocardial infarction,percutaneous coronary intervention,thrombosis

Data availability:

Keywords: biomarker, clopidogrel, myocardial infarction, percutaneous coronary intervention, thrombosis

Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention.

Read this article at

Abstract

Related collections

Karger: Cardiovascular System

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 72

Cited by 4